Cancer Research in Switzerland - Krebsliga Schweiz

More documents

Recommendations

Info

14 Quotas were introduced in 2002 and have since proved to be an effective instrument for increased support of patient-centred research; they are planned to remain in place in the future. Whereas in 2001, 2002, and 2003 35 % of the funds for independent project research went to patient-centred research and 65 % to basic research, the cumulative percentage of funds for clinical, psychosocial, and epidemiological research has since been at a much higher level and a stable one of 45 % and more since 2004 (Table 4). At the same time, it is apparent that this instrument alone is not sufficient to achieve the quota of 60 % for patient-centred research. This is especially due to the fact that too few grant applications have been submitted from these areas that meet the high standards of quality. And the most heavily weighted criterion in the decision to fund research is still the criterion of highest quality research. Simplified submission procedure To lower the threshold for submission of proposals from underrepresented disciplines in patient-centred research a simplified, two-step submission procedure was introduced. This instrument proved to have only limited success. Of the total 105 originally submitted shorter letters of intent in the period 2004–2009, only 22 led to a research project that was approved Table 4 Distribution of funds for independent research projects by research area and year for funding, which is a success rate of only 21%. For this reason, this instrument, which also entailed a lot of effort for the evaluation process, was discontinued in 2010. Programme research In 2003 two special research programmes were launched: Collaborative Cancer Research Projects (CCRP) and International Clinical Cancer Research Groups (ICP). The CCRP programme provided targeted funding to translational research: Through supporting close collaboration between basic and clinical researchers, the aim was for basic research to move faster from discoveries in the laboratory to actual clinical applications. The ICP programme supported already existing international research collaborations that are coordinated by Switzerland (see also the section on programme research on page 42). After the launch of the research programmes, in the period 2004–2010 a total CHF 14.7 million was invested in this instrument, including CHF 10.1 million in six CCRP that are not yet completed. A critical evaluation of the results of the CCRP showed that these projects, which have a longer duration of five years, lock up too large a portion of the total funds available. Moreover, the desired translational added 2003 2004 2005 2006 2007 2008 2009 2010 Basic biomedical research Total in million CHF 4,75 6,00 4,18 5,14 6,12 4,35 4,80 7,00 in % 65 % 56 % 49 % 52 % 56 % 48 % 47 % 59 % Clinical research Total in million CHF 2,19 3,31 3,36 3,31 3,85 2,90 3,96 3,14 in % 30 % 31 % 40 % 33 % 35 % 32 % 39 % 26 % Psychosocial research Total in million CHF 0,14 1 0,61 0,74 1,05 0,84 0,7 0,36 in % 2 % 9 % 7 % 7 % 10 % 9 % 7 % 3 % Epidemiological research Total in million CHF 0,22 0,37 0,31 0,74 0 0,93 0,74 1,40 in % 3 % 3 % 4 % 7 % 0 % 10 % 7 % 12 % All projects Total in million CHF 7,30 10,68 8,46 9,93 11,02 9,02 10,20 11,90
value was not clearly discernible. It was also unclear whether the collaborations between laboratory and clinic supported by the CCRP will continue in the longer term. For this reason, there have been no more calls for proposals under the CCRP programme since 2009. Naturally, translational research projects continue to be funded via independent project research. Calls for proposals were also discontinued in 2009 for the ICP programme. Two ongoing ICP will be completed in 2011: the International Childhood Liver Tumour Consortium and the International Extranodal Lymphoma Study Group (IELSG). In total, seven ICP were funded with a total of CHF 4.6 million. This instrument for promoting programme research was replaced by financial contributions to clinical cancer research institutions in Switzerland. Supporting clinical cancer research organizations In 2009 the boards of the SCL and CRS decided to change the strategy regarding support for cancer research organizations: Now, by means of performance agreements, important basic services are funded that diverse organizations perform within clinical cancer research, such as designing study protocols, managing data, obtaining authorizations from ethics committees and Swissmedic, coordinating multi-centre studies and international studies, and others. Through the structural contributions for specific activities, the aim is to reward and ensure the work of the organizations in the longer term. The following organizations were supported by the SCL in the reporting period 2009–2010: – Swiss Group for Clinical Cancer Research (SAKK): This non-profit organization has launched and coordinated clinical cancer trials in Switzerland and abroad since 1965. SAKK comprises a wide network of about 20 Swiss research groups and the SAKK Coordinating Centre in Bern. SAKK receives a contribution of CHF 600,000 per year. – International Breast Cancer Study Group (IBCSG): This study group has conducted academic clinical trials in breast cancer since 1977. It is dedicated to improving the treatment of women with breast cancer. IBCSG receives an annual contribution of CHF 560,000. – Swiss Paediatric Oncology Group (SPOG): This association is an academic research organization focusing on clinical, patient-centred research in paediatric oncology, particularly in the frame work of national collaborative studies. The SPOG receives CHF 100,000 per year. On the part of CRS, a maximum CHF 2 million, or maximum 20 % of the total research funding budget, is reserved for this instrument. These monies are used by CRS for targeted financial support of five to six research organizations. Dr. Rolf Marti, PhD Rolf Marti has headed the Scientific Office since 2002 and is responsible for research funding. He is a member of the managing board of the Swiss Cancer League and director of Foundation Cancer Research Switzerland. One of the focuses of his work is research policy. Phone +41 (0)31 389 91 45 rolf.marti@swisscancer.ch www.swisscancer.ch/research 15
Page 1 and 2: Cancer Research in Switzerland A pu
Page 3 and 4: Cancer Research in Switzerland
Page 5 and 6: Basic biomedical research 55 Cancer
Page 7 and 8: policy work and was in charge of de
Page 9 and 10: The main focus of the research fund
Page 11 and 12: gramme research funding decreased b
Page 13 and 14: Table 2 Distribution of funds for i
Page 15: Funding patient-centred research Pa
Page 19 and 20: New organization of the Foundation
Page 21 and 22: The board of the Foundation Cancer
Page 23 and 24: The president of the Scientific Com
Page 25 and 26: Prof. Martin Pruschy, PhD Departmen
Page 27 and 28: Swartz wants to find out how tumour
Page 29 and 30: The scientific and medical research
Page 31 and 32: 3. The original order/sequence of t
Page 33 and 34: As a federation, the Cancer League
Page 35 and 36: List of funded research projects, i
Page 37 and 38: Zippelius Alfred | 2009: CHF 100,00
Page 39 and 40: Kridel Robert | 2010: CHF 100,000.-
Page 41 and 42: Thurgau Cancer League Biotechnologi
Page 43 and 44: Weller Michael | 2010: CHF 65,828.-
Page 45 and 46: manageable funding of individual pr
Page 47 and 48: enhances breast cancer cell motilit
Page 49 and 50: Rüegg Curzio et al. | Tumor-mediat
Page 51 and 52: International Clinical Cancer Resea
Page 53 and 54: in PHIV were shown for Hodgkin’s
Page 55: Zucca Emanuele et al. | Internation
Page 58 and 59: 56 “hierarchical structure” of
Page 60 and 61: 58 the attempt should be made to st
Page 62 and 63: 60 Gönczy Pierre | KLS 0202402
Page 64 and 65: 62 Romero Pedro | OCS 020110220
Page 66 and 67:
64 Beermann Friedrich | In vivo scr
Page 68 and 69:
66 Christofori Gerhard | Podoplanin
Page 70 and 71:
68 Frei Christian | The function of
Page 72 and 73:
70 cell, this novel mechanism serve
Page 74 and 75:
72 Results The induction of viral p
Page 76 and 77:
74 Hübscher Ulrich | Repair of oxi
Page 78 and 79:
76 Methods and experimental approac
Page 80 and 81:
78 of cMyc and/or NMyc and demo
Page 82 and 83:
80 In summary, this work improves o
Page 84 and 85:
82 Pruschy Martin | Microtubule int
Page 86 and 87:
84 Renner Christoph | Selective inh
Page 88 and 89:
86 Goal Here we build on these obse
Page 90 and 91:
88 by TDG prevents efficient downst
Page 92 and 93:
90 To address these questions, we a
Page 94 and 95:
92 Translational relevance The resu
Page 96 and 97:
94 Grünberg Jürgen | KFS 025460
Page 98 and 99:
96 Tschan Mario P. | KFS 0248608
Page 100 and 101:
98 Boyman Onur | Preclinical testin
Page 102 and 103:
100 Constam Daniel | Role of activi
Page 104 and 105:
102 this study we will examine the
Page 106 and 107:
104 Janscak Pavel | Study of the ro
Page 108 and 109:
106 Müller Anne | The molecular pa
Page 110 and 111:
108 Radtke Freddy | The role of Not
Page 112 and 113:
110 Schär Primo | DNA repair, epig
Page 114 and 115:
112 In this project we will investi
Page 116 and 117:
114
Page 118 and 119:
116 and Research). Other financial
Page 120 and 121:
118 be totally unaffordable for aca
Page 122 and 123:
120 Clinical research List of compl
Page 124 and 125:
122 Hunger Robert E. | OCS 02262-08
Page 126 and 127:
124 Clinical research Presentation
Page 128 and 129:
126 Benhattar Jean | Identification
Page 130 and 131:
128 Bertoni Francesco | Genome-wide
Page 132 and 133:
130 Interpretation ESA treatment in
Page 134 and 135:
132 Our results could pave the way
Page 136 and 137:
134 new drugs that specifically tar
Page 138 and 139:
136 slides in two different concent
Page 140 and 141:
138 Conclusions A strong network of
Page 142 and 143:
140 tions introduced to ARE motifs
Page 144 and 145:
142 Müller Beatrice U. | The maste
Page 146 and 147:
144 A novel method was developed fo
Page 148 and 149:
146 (SAKK 35-98) the Swiss Group fo
Page 150 and 151:
148 Timmermann Beate | Prospective
Page 152 and 153:
150 recurrence of the disease, we a
Page 154 and 155:
152 Zucca Emanuele | A prospective
Page 156 and 157:
154 Heinimann Karl | KFS 02489-08-2
Page 158 and 159:
156 Riggi Nicolò | BIL KFS 02717-0
Page 160 and 161:
158 activity at the single cell lev
Page 162 and 163:
160 Our research projects aim at un
Page 164 and 165:
162 Körner Meike | In vitro evalua
Page 166 and 167:
164 Nadal David | Is endemic Burkit
Page 168 and 169:
166 (> 50.000/patient). For their a
Page 170 and 171:
168 Zeller Rolf | Functional analys
Page 172 and 173:
170
Page 174 and 175:
172 area of health services researc
Page 176 and 177:
174 The financing of palliative car
Page 178 and 179:
176 National Strategy for Palliativ
Page 180 and 181:
178 Psychosocial research List of c
Page 182 and 183:
180 Within the patient group, level
Page 184 and 185:
182 Further, the results suggest th
Page 186 and 187:
184 It is in this context that the
Page 188 and 189:
186 Recommendation Female spouses o
Page 190 and 191:
188 Psychosocial research Presentat
Page 192 and 193:
190 rates communication skills rema
Page 195 and 196:
Epidemiological research Epidemiolo
Page 197 and 198:
data from cancer registries. In the
Page 199 and 200:
The importance of cancer registries
Page 201 and 202:
Ess Silvia | Patterns of care and s
Page 203 and 204:
Epidemiological research List of ap
Page 205 and 206:
Impact This work will serve as the
Page 207 and 208:
Thürlimann Beat | Management of br
show all

Cancer Research in Switzerland - Krebsliga Schweiz

Create successful ePaper yourself

Delete template?

Save as template?